News & Updates

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 by

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023

Machine perfusion delivers positive outcomes for liver transplantation

18 Nov 2023

Machine perfusion techniques are effective and appear to be better than static cold storage (SCS) in patients who underwent liver transplantation, suggest the results of a meta-analysis.

Machine perfusion delivers positive outcomes for liver transplantation

18 Nov 2023

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 by

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

23 Oct 2023 by

Waitlisted registrants for liver transplantation (LT) who have nonalcoholic steatohepatitis (NASH) cirrhosis have a lower chance to receive a new organ and greater risk of waitlist mortality at 90 days and 1 year than patients with non-NASH cirrhosis, suggest the results of a Singapore study.

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

23 Oct 2023

Obeticholic acid shows therapeutic potential in LPAC syndrome

22 Oct 2023

The selective farnesoid-X receptor agonist obeticholic acid appears to improve symptoms of low phospholipid-associated cholelithiasis (LPAC) syndrome in patients who have inadequate response or intolerance to ursodeoxycholic acid, as shown in a small study.

Obeticholic acid shows therapeutic potential in LPAC syndrome

22 Oct 2023

Pegozafermin shows promise in NASH patients

13 Oct 2023

In the treatment of patients with nonalcoholic steatohepatitis (NASH), the glycoPEGylated FGF21 analogue pegozafermin appears to confer beneficial effects on hepatic and metabolic parameters while being well tolerated, according to the results of a phase 1b/2a clinical trial.

Pegozafermin shows promise in NASH patients

13 Oct 2023

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

04 Oct 2023

Treatment with 5-methyltetrahydrofolate (5-MTHF) significantly enhances the effect of propranolol in reducing hepatic venous pressure gradient (HVPG) in patients with cirrhosis and portal hypertension, a recent study has shown.

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

04 Oct 2023

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

04 Oct 2023

The combination of hepatocyte-derived biomarkers and FibroTest or model for end-stage liver disease (MELD) scores can help identify patients with Child-Pugh class A alcohol-related cirrhosis who are prone to liver-related events at 2 years, reports a study.

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

04 Oct 2023

News & Updates

Filter by Specialty:

Specialty:

8-week TAF course enough to prevent mother–child HBV transmission

8-week TAF course enough to prevent mother–child HBV transmission

Machine perfusion delivers positive outcomes for liver transplantation

Machine perfusion delivers positive outcomes for liver transplantation

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

Obeticholic acid shows therapeutic potential in LPAC syndrome

Obeticholic acid shows therapeutic potential in LPAC syndrome

Pegozafermin shows promise in NASH patients

Pegozafermin shows promise in NASH patients

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis